News
Researchers from more than 50 international institutions have launched Open Problems, a collaborative open-source platform to ...
Discover the potential of Single Cell Genomics in our latest report. As it revolutionizes healthcare, identify opportunities, growth expectations, and market potential. Stay ahead with insights ...
Despite still being considered emerging techniques, single cell and spatial technologies have brought ground-breaking ...
BioSkryb Genomics is a rapidly growing organization that is transforming single-cell molecular discovery and analysis. Through its single-cell whole genome and transcriptome amplification tools and ...
According to SNS Insider, the global Single-Cell Sequencing Market was valued at USD 2,109.8 million in 2023 and is projected to reach USD 7,420.8 million by 2032, expanding at a CAGR of 15% over ...
6.39 Single-Cell Genomics 6.40 Namocell, Takara Bio, HepaTx Partner on Single-Cell Genomics 6.41 Vizgen Launches With $14M Series A Financing 6.42 SeqWell Raises $9M in Series B Round. 7 Profiles ...
BioSkryb Genomics and Tecan Group, today introduced a high-throughput single-cell workflow, combining BioSkryb's 384-well format of the ResolveOME™ Whole Genome and Transcriptome Single-Cell ...
According to SNS Insider, the global Single-Cell Sequencing Market was valued at USD 2,109.8 million in 2023 and is projected to reach USD 7,420.8 million by 2032, expanding at a CAGR of 15% over ...
DURHAM, N.C. & MÄNNEDORF, Switzerland--(BUSINESS WIRE)-- BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb ...
BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb's 384-well format of the ResolveOME(TM) Whole Genome and ...
BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME™ Whole Genome and ...
BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME™ Whole Genome and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results